• In February 2025, Eli Lilly launched a Phase II pediatric trial for a novel norepinephrine-dopamine modulator for developmental motor delays. Eli Lilly initiated a mid-stage clinical study to assess a new agent that targets norepinephrine and dopamine pathways, aiming to improve motor planning and execution in children with developmental dyspraxia. This reflects the growing emphasis on neurochemical modulation in pediatric motor disorders.
• In December 2024, Neurocrine Biosciences announced a breakthrough patent for a cognitive enhancer targeting verbal dyspraxia. Neurocrine Biosciences secured a patent for a novel cognitive enhancer formulated to support speech coordination and verbal processing in children with verbal dyspraxia, marking a significant advancement in pharmacologic options for language-specific motor impairments.
• In September 2024, Pfizer submitted regulatory filings for an extended-release formulation of a nootropic compound for use in DCD. Pfizer submitted applications to regulatory authorities for approval of an extended-release nootropic designed to support executive functioning, attention, and motor learning in children with developmental coordination disorder, offering improved adherence through simplified dosing.
• In July 2024, Takeda partnered with a U.S. academic center to develop dual-action drugs for co-occurring dyspraxia and anxiety in children. Takeda formed a strategic research partnership to co-develop pharmacologic solutions that address both motor coordination issues and anxiety symptoms in pediatric patients, aiming to provide more comprehensive care through combination therapy approaches.
